OPTION AND LICENSE AGREEMENT (AGEN2373) by and between AGENUS INC. and GILEAD SCIENCES, INC. dated as of December 20, 2018Option and License Agreement • March 18th, 2019 • Agenus Inc • Biological products, (no disgnostic substances) • New York
This OPTION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of December 20, 2018 (the “Execution Date”) by and between Agenus Inc., a Delaware corporation (“Agenus”) and Gilead Sciences, Inc., a Delaware corporation (“Gilead”). Agenus and Gilead are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
LICENSE AGREEMENT by and between AGENUS INC. and GILEAD SCIENCES, INC. dated as of December 20, 2018License Agreement • March 18th, 2019 • Agenus Inc • Biological products, (no disgnostic substances) • New York
The applicable royalty rate set forth in the table above shall apply only to that portion of the Annual Net Sales of a given Licensed Product during a given Calendar Year that falls within the indicated range. [******].
ContractCommon Stock Purchase Agreement • March 18th, 2019 • Agenus Inc • Biological products, (no disgnostic substances) • New York
[******] - Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
